20.500.12556/DiRROS-8195
Anti PD-1 protitelesa : uporaba, delovanje, neželeni učinki
Anti-PD-1 antibodies : use, action, side effects
Protein programirane celične smrti 1:PD-1 (Programmed cell death protein 1) je transmembranski protein, ki je izražen na celicah T, B, NK ter monocitih in dendritičnih celicah. Vezava med PD-1 in njegovimi ligandi zavira tumorsko celično apoptozo, spodbuja izčrpanost T-celic in preprečuje aktiven antitu¬morski odziv, kar posledično omogoča nemoteno rast in razvoj tumorskih celic. Zaviralca receptorja PD-1, pembrolizumab in nivolumab, že uporabljamo v zdravljenju različnih vrst napredovalega raka, kot so: melanom, nedrobnocelični karcinom pljuč, Hodgkinov limfom in karcinom ledvic. Na zdravljenje odgovori zelo različno število bolnikov, kar je odvisno od indikacije in linije zdravljenja, to je od pri 18 do 80 odstotkih bolnikov. Posebnosti zdravljenja z imuno¬terapijo so zelo dolgotrajne remisije, pri posameznih bolnikih pa bomo morebiti upali govoriti celo o ozdravitvi. Najpogostejši neželeni učinki so utrujenost, srbečica, izpuščaji, driska in slabost. Najresnejši neželeni učinki so imunsko pogojeni neželeni učinki in hude z infuzijo povezane reakcije. Imunsko pogojeni neželeni učinki so kolitis, tiroiditis, pneumonitis, hepatitis in nefritis.
Programmed cell death protein 1 (PD-1) is a transmembrane protein expressed in T, B, NK cells, monocytes, and dendritic cells. The binding of PD-1 to its ligands inhibits tumor cell apoptosis, stimulates T-cell depletion, and prevents active antitumor response, which consequently enables an uninhibited growth and development of tumor cells. PD-1 receptor inhibitors pembrolizumab and nivolumab are already used in the treatment of various types of advanced cancer, such as melanoma, non-small cell lung cancer, Hodgkin’s lymphoma, and renal carcinoma. Depending on the indication and line of treatment, a different number of patients responds to the treatment success¬fully, ranging from 18 % to 80 % of patients. The particularities of treatment with immunotherapy include very long-lasting remissions and, in individual patients, we might even dare talk about cure. The most common side effects are fatigue, pruritus, rash, diarrhea, and nausea. Among the most serious side effects are immune-rela¬ted adverse reactions – including colitis, thyroiditis, pneumonitis, hepatitis, and nephritis – and severe infusion-related reactions.
imunoterapija
anti-PD-1 protitelesa
zaviralci receptorjev
true
false
true
Slovenski jezik
Angleški jezik
by Authors
Neznano
2018-03-16 11:29:08
2018-03-16 11:29:09
2022-08-16 09:59:14
0000-00-00 00:00:00
2017
0
0
str. 22-25
št. 2
Letn. 21
dec. 2017
0000-00-00
Zaloznikova
Objavljeno
NiDoloceno
0000-00-00
0000-00-00
0000-00-00
616-006
1408-1741
2841467
65324032
RAZ_Ocvirk_Janja_i2017.pdf
RAZ_Ocvirk_Janja_i2017.pdf
1
B3823B0B5E4DB54721A500EAB10D2292
81aa7d73da6907d6ca25510ce155cdad493ede928842577a68c7e7b91527338c
46bfad8d-17b5-11ed-b6b8-001a4af901a5
20.500.12556/dirros/30c34c6e-d6a2-412a-9995-880cc3f11228
https://dirros.openscience.si/Dokument.php?lang=slv&id=10088
Onkološki inštitut Ljubljana
Onkologija : strokovni časopis za zdravnike
0
0
0